Srinath Tadakamalla, MD
Geriatric Medicine · Harrisonville, MONPI 1184691305
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,832 of the $81,724 with a category attached, or 73.2%. Acadia Pharmaceuticals Inc accounts for 79.7% of it on its own, with 21 other manufacturers making up the rest. Among geriatric medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $356.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$65K
- Urovant Sciences Inc$7K
- Axsome Therapeutics, Inc.$6K
- Alpha Cognition USA, Inc.$900
- Avanir Pharmaceuticals, Inc.$544
- Neurocrine Biosciences, Inc.$474
- plus $2K from 16 others
What the payments were for
- Consulting fees$8,95011%
- Speaking & faculty fees$59,83273%
- Travel & lodging$5,2896%
- Food & beverage$7,6069%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 140 | $65,105 |
| Urovant Sciences Inc | 10 | $6,901 |
| Axsome Therapeutics, Inc. | 3 | $5,861 |
| Alpha Cognition USA, Inc. | 1 | $900 |
| Avanir Pharmaceuticals, Inc. | 8 | $544 |
| Neurocrine Biosciences, Inc. | 6 | $474 |
| Vanda Pharmaceuticals Inc. | 9 | $295 |
| Otsuka America Pharmaceutical, Inc. | 13 | $210 |
| AstraZeneca | 3 | $205 |
| Medline Industries LP | 1 | $168 |
| UCB, Inc. | 5 | $144 |
| Abbott | 1 | $141 |
| Sumitomo Pharma America, Inc. | 9 | $131 |
| Mylan Specialty L.p. | 1 | $116 |
| Sunovion Pharmaceuticals Inc. | 9 | $110 |
| Smith+Nephew | 1 | $109 |
| Radius Health, Inc. | 1 | $100 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $96 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Protega Pharmaceutials Inc | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,724 in reported general payments places this provider in the 95th percentile of 76 geriatric medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 4,115 | $1,232,451 |
| JardianceEmpagliflozin | 1,050 | $330,945 |
| XareltoRivaroxaban | 819 | $232,425 |
| Invega SustennaPaliperidone Palmitate | 77 | $201,415 |
| AustedoDeutetrabenazine | 31 | $184,431 |
| Humira PenAdalimumab | 25 | $184,392 |
| NuplazidPimavanserin Tartrate | 60 | $182,483 |
| GemtesaVibegron | 709 | $175,889 |
| NuedextaDextromethorphan Hbr/Quinidine | 237 | $173,479 |
| FarxigaDapagliflozin Propanediol | 528 | $161,793 |
| MyrbetriqMirabegron | 670 | $155,210 |
| SantylCollagenase Clostridium Hist. | 174 | $152,316 |
| OzempicSemaglutide | 116 | $119,540 |
| EnbrelEtanercept | 15 | $117,525 |
| TrulicityDulaglutide | 140 | $113,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $49 | $271,82657 claims |
| Acadia Pharmaceuticals IncNuplazid | $65,105 | $182,48360 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $131 | $175,889709 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $544 | $173,479237 claims |
| AstraZenecaFarxiga | $205 | $161,793528 claims |
| Smith+NephewSantyl | $109 | $152,316174 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $210 | $102,677146 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $474 | $55,09415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 geriatric medicine providers in Missouri.
Other geriatric medicine in Harrisonville
- Randall HalleyColumbia$18K
- Angela SanfordSaint Louis$15K
- Madhu SahaiSikeston$6K
- John MorleySt Louis$6K
- Karmel CarothersIndependence$5K
- William KnappFlorissant$5K
- Ellen BinderSaint Louis$4K
- Poonam JainSaint Louis$4K
- Uchenna OgbuokiriSaint Louis$3K
- Charles CreceliusSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.